Interim data from Akeso’s Phase 3 HARMONi-2 study of ivonescimab PD-1/VEGF bispecific antibody demonstrated a statistically significant and clinically meaningful improvement over Pembrolizumab in non-small cell lung cancer with tumours expressing PD-L1.